Quantcast

Latest Novartis Stories

2014-05-19 16:24:18

Appoints Nicholas A. Saccomano, Ph.D. as Chief Scientific Officer and Robert E. Winkler, M.D. as Vice President of Clinical Development BOULDER, Colo., May 19, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, today announced the appointments of Nicholas A. Saccomano, Ph.D., as Chief Scientific Officer and Robert E....

2014-05-19 08:28:56

DUBLIN, May 19, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/rd8s6p/meningococcal) has announced the addition of the "Global Meningococcal Vaccines Market - Forecasts to 2019: Sanofi, Novartis, GlaxoSmithKline, Pfizer, Serum Institute of India, JN-International, Nuron, Baxter and Biomed" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Meningococcal disease caused by the bacterium Neisseria meningitidis is a life...

2014-05-15 12:35:20

LONDON, May 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Ophthalmic Drugs: World Market Prospects 2013-2023http://www.reportbuyer.com/pharma_healthcare/treatments/eye_care/ophthalmic_drugs_world_market_prospects.html Report DetailsHow to find trends and revenue predictions for the ophthalmic drug industryWhat are the commercial prospects for treating eye disorders? Visiongain's new report gives you forecasted revenues to 2023. It explains trends,...

2014-05-15 12:34:27

LONDON, May 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Antibacterial Drugs: World Market Prospects 2013-2023http://www.reportbuyer.com/pharma_healthcare/generic_drugs/antibacterial_drugs_world_market_prospects.html Report DetailsDiscover new trends, opportunities and revenue prospects for bacteria-killing medicinesWhere's the antibiotics market heading? How are those products performing? Visiongain's updated report gives you forecasted revenues...

2014-05-14 08:30:37

BOULDER, Colo., May 14, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced presentations on its MEK inhibitors, binimetinib (MEK162) (co-developing with Novartis) and selumetinib (licensed to AstraZeneca) at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 30 - June 3, 2014 in Chicago, Illinois. Both MEK inhibitors are advancing in Phase 3 or pivotal trials: binimetinib is being evaluated in NRAS- and BRAF-mutant...

2014-05-12 08:31:45

GAITHERSBURG, Md., May 12, 2014 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the first quarter ended March 31, 2014. For the three months ended March 31, 2014, the company reported a net loss of $1.0 million, or $0.07 per share on revenues of $2.1 million compared with a net loss of $3.0 million, or $0.24 per share on revenues of $1.2 million, for the same period in the prior year. GenVec ended the first quarter of 2014 with $15.3 million in cash,...

2014-05-08 08:34:10

MIDDLESEX, N.J., May 8, 2014 /PRNewswire/ -- CorePharma, LLC ("CorePharma"), a developer, manufacturer, and marketer of targeted generic prescription pharmaceuticals, announced today that it has launched Methylphenidate Hydrochloride Tablets USP ("Methylphenidate"), the generic version of Novartis' Ritalin®. Methylphenidate is indicated for the treatment of narcolepsy and attention deficit disorders. CorePharma received final approval from the U.S. Food and Drug Administration (FDA)...

2014-05-08 08:32:34

JUPITER, Fla., May 8, 2014 /PRNewswire/ -- Charleston Laboratories, Inc., an emerging specialty pharmaceutical company focused on the research and development of novel pain products, today announced the company has appointed two new members to its senior executive team. Joseph Hazelton joined the company in the newly created position of Executive Vice President, Chief Commercial Officer, and Michael G. McCully joined the company in the newly created position of Executive Vice...

2014-05-01 20:24:02

DUBLIN, May 1, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/dfhjv9/global_orphan) have announced the addition of the "Global Orphan Drugs Market 2014-2018" [http://www.researchandmarkets.com/research/dfhjv9/global_orphan ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The analysts forecast the Global Orphan Drugs market to grow at a CAGR of 5.67 percent over the period 2013-2018....

2014-04-29 20:23:44

LONDON, April 29, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:The World Market for Orphan Drugshttp://www.reportbuyer.com/pharma_healthcare/therapeutic/world_market_orphan_drugs_1.htmlIn recent years, there has been a substantial increase in the number of drugs available to treat rare ("orphan") diseases. This comprehensive report, The World Market for Orphan Drugs, looks at this trend and provides estimates for the market opportunity in the U.S.,...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related